Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and a Favorable Safety Profile

Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares